All type of patients: 1 trials - BRAVO
| niraparib vs Physician s choice chemotherapy | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | treatment discontinuation due to toxic effects | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
BRCA-mutated: 1 trials - BRAVO
| niraparib vs Physician s choice chemotherapy | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | treatment discontinuation due to toxic effects | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient (BRCA mutated or not): 2 trials - ENGOT-OV16/NOVA non-gBRCA - ENGOT-OV16/NOVA gBRCA
| niraparib vs placebo | No demonstrated result suggested progression or death (progression free survival PFS) by 62% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.38 [0.30 0.49] | p=0.04 | 0 | 406 | 2 | ENGOT-OV16/NOVA non-gBRCA,ENGOT-OV16/NOVA gBRCA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
